COMMUNIQUÉS West-GlobeNewswire

Santhera Secures Agreement with GEN for the Distribution of AGAMREE® (Vamorolone) in Türkiye
13/08/2025
Pratteln, Switzerland , 13 August , 2025 – Santhera Pharmaceuticals (SIX: SANN) announces the signing of an exclusive agreement with Gen İlaç ve Sağlık Ürünleri San. ve Tic. A.Ş. (GEN) for the distribution and promotion [...]
Greywolf Therapeutics begins dosing of the first treatment to target the antigenic source of autoimmunity
13/08/2025
This is the first ever autoimmunity study to evaluate a potential functional cure that targets the antigenic source – the origin of autoimmune disease The Phase 1/2 study (up to 141 participants) will evaluate the [...]
Compass Therapeutics Announces Pricing of Upsized $120 Million Public Offering
13/08/2025
BOSTON, Aug. 12, 2025 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (“Compass”) (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat [...]
Fate Therapeutics Reports Second Quarter 2025 Financial Results and Business Updates
12/08/2025
First patient treated with FT819 off-the-shelf CAR T-cell product candidate following fludarabine-free conditioning for severe lupus nephritis demonstrated durability of response with drug-free definition of remission [...]
Lyra Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update
12/08/2025
– Positive ENLIGHTEN 2 Phase 3 results announced in June 2025 propel business activities in manufacturing, regulatory strategy and ENLIGHTEN clinical dataset analysis to advance path forward for LYR-210 for treatment of [...]
Nkarta Reports Second Quarter 2025 Financial Results and Corporate Highlights
12/08/2025
Initial update for NKX019 in multiple autoimmune indications expected in second half of 2025 Cash balance of $334.0 million on June 30, 2025, including cash, cash equivalents and investments, expected to fund operations [...]
Verrica Pharmaceuticals Reports Second Quarter 2025 Financial Results
12/08/2025
– Company reports $12.7 million in revenue in Q2’25, consisting primarily of $4.5 million in YCANTH ® revenue, net, reflecting sequential growth of 32.5% over Q1’25 and $8.0 million in milestone revenue from Torii [...]
Editas Medicine Announces Second Quarter 2025 Results and Business Updates
12/08/2025
Company to select lead development candidate in September; on track to file IND by mid-2026 and achieve human proof-of-concept by year-end 2026 First IND/CTA accepted for CD19 HD Allo CAR T program as part of [...]
Erasca Reports Second Quarter 2025 Business Updates and Financial Results
12/08/2025
Efficient execution accelerated clinical entry of pan-RAS molecular glue ERAS-0015 and pan-KRAS inhibitor ERAS-4001 Phase 1 monotherapy data for RAS-targeting franchise expected in 2026 Robust balance sheet with cash, [...]
Compass Therapeutics Announces Proposed Public Offering
12/08/2025
BOSTON, Aug. 12, 2025 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (“Compass”) (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat [...]
Journey Medical Corporation Reports Second Quarter 2025 Financial Results and Recent Corporate Highlights
12/08/2025
S econd quarter 2025 revenues were $15.0 million Emrosi™ net sales of $2.8 million generated in first full quarter on the market The Company joined the Russell 2000® and Russell 3000® Indexes in June 2025 Company to [...]
Maze Therapeutics Reports Second Quarter 2025 Financial Results and Recent Highlights
12/08/2025
MZE782 Phase 1 Trial in Healthy Volunteers to Provide Proof of Mechanism Data for Phenylketonuria (PKU) and Chronic Kidney Disease (CKD) Expected in Q3 2025 MZE829 Phase 2 HORIZON Trial Actively Enrolling Patients with [...]
Kyverna Therapeutics Provides Business Update and Reports Second Quarter 2025 Financial Results
12/08/2025
Topline data for registrational Phase 2 trial of KYV-101 in stiff person syndrome (SPS) and BLA submission anticipated in 1H 2026 Registrational Phase 3 KYV-101 trial in myasthenia gravis (MG) to include ~60 patients [...]
ORIC® Pharmaceuticals Reports Second Quarter 2025 Financial Results and Operational Updates
12/08/2025
Reported potentially best-in-class clinical efficacy and safety data from ongoing Phase 1b trial of ORIC-944 in combination with AR inhibitors for the treatment of patients with mCRPC Strengthened cash position with $ [...]
NEXGEL Reports Second Quarter 2025 Financial Results
12/08/2025
Second quarter 2025 revenue totaled $2.88 million, an increase of 100.3% as compared to $1.44 million for the same period year-over-year Gross Profit for the quarter was 43.6%, compared to 20.3% for the same period in [...]
Cytek Biosciences to Participate in Upcoming Investor Conferences
12/08/2025
FREMONT, Calif., Aug. 12, 2025 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (Nasdaq: CTKB), a leading cell analysis solutions company, today announced the company will be participating in the following investor [...]
BioRestorative Therapies Reports Second Quarter 2025 Financial Results and Provides Business Update
12/08/2025
MELVILLE, N.Y., Aug. 12, 2025 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc . (“BioRestorative”, “BRTX” or the “Company”) (NASDAQ: BRTX ) , a regenerative medicine innovator focused on stem cell-based therapies and [...]
Mineralys Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update
12/08/2025
– Presented and published the positive results from both the Launch-HTN and Advance-HTN pivotal trials at scientific meetings and in JAMA and NEJM – – Pre-NDA meeting scheduled to take place in 4Q 2025 – – Explore-CKD [...]
Pharvaris Reports Second Quarter 2025 Financial Results and Provides Business Update
12/08/2025
Topline results for RAPIDe-3, a pivotal Phase 3 study of deucrictibant for the on-demand treatment of HAE attacks, expected in 4Q2025 Enrollment continues in CHAPTER-3, a pivotal Phase 3 study of deucrictibant for [...]

Pages